



Young Kwang Chae

Northwestern University Feinberg School of Medicine, USA

Dr. Young Kwang Chae is currently the co-director of the Early Phase Clinical Trials Unit of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University in Chicago, IL. He is also the co-director of the Developmental Therapeutics Fellowship program in the Division of Hematology/Oncology at the Northwestern University Feinberg School of Medicine. He received his MD from the Seoul National University in South Korea in 2002, as well as his MPH and MBA from John Hopkins University in Baltimore, Maryland in 2007. He completed his residency in internal medicine at the Albert Einstein Medical Center in Philadelphia, Pennsylvania in 2011, followed by his fellowship in Hematology/Oncology at the University of Texas M.D. Anderson Cancer Center in Houston, TX in 2014. He has received numerous honors, awards, and grants, and has over 70 publications.

Dr. Chae's main focus is in designing and conducting innovative early phase clinical trials and their translational medicine research. Dr. Chae is in charge of many targeted therapy clinical trials and immunotherapy combination trials and biomarker studies within and outside Northwestern University. He is the current principal investigator (PI) of the NCI MATCH arm W (FGFR inhibitor) and one of the study chairs and translational medicine PI of the SWOG S1609 DART trial for rare tumors. He is also active member of the SWOG early therapeutics & rare cancer committee and lung committee. He believes that his clinic is his lab and wants to bridge the gap between the cutting-edge science and clinical medicine. He also is an expert in the field of cancer biomarkers including circulating tumor DNA and tumor mutational burden. Above all, his passion is to help desperate patients including those with rare cancers who do not have standard of care treatment options or have become refractory to all existing treatment options with novel treatments through well designed clinical trials bringing the best science to patients. He plans to facilitate incorporation of novel translational science into high-impact clinical trials.